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Background: Treatment and prophylaxis of sepsis in very low birth weight neonates is a matter of concern and
research is being undertaken with the aim to give rise to shared approaches based on solid evidence. As part of a
European initiative, a survey was set up to describe the use of two drugs in this area. The Italian national practices
concerning neonatal sepsis, as well as calls for related guidance, are described.
Methods: A standardized and previously tested questionnaire was submitted online to all Italian level III NICUs.
A 5-point Likert scale was used to analyze attitudinal replies. Categorical variables were compared by χ2 analysis
and 2-tailed P-values are reported.
Results: Data was provided by 38 Italian NICUs (36% of the country’s level III centers), 53% of which have 1–10
cases of bacterial sepsis monthly and 90% a prevalence of <1% fungal infections. Ciprofloxacin and fluconazole
treatment for neonatal sepsis are scantly used in Italian NICUs (13% and 45%, respectively). Major concerns are
related to the safety of ciprofloxacin and the efficacy of fluconazole. On the contrary, prophylaxis of fungal
infections is a routine approach in many Italian NICUs. The use of both ciprofloxacin and fluconazole is
characterized by a large inter-NICU variability in dose and scheme of use. The lack of adequate, shared evidence is
a common consideration made by the survey participants.
Conclusions: Common approaches are needed to standardize and update a national drug strategy for the
prevention and treatment of sepsis in very low birth weight newborns. This can be achieved through collaborative
initiatives aimed at setting up guidelines, based on available data, and multicenter trials to produce new evidence
that will address the knowledge gaps.
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Practice guidelines as topicBackground
Sepsis in neonates can be caused by bacterial or fungal
microorganisms and is associated with significant morbid-
ity and mortality. Up to one fourth of very-low-birth
weight infants (VLBW; <1500 g at birth) develop hospital-
acquired infections.
Studies have assessed the use prophylactic measures to
prevent infections, but data on treatment and prophy-
laxis is lacking [1-3]. Empirical antibiotic therapy is often
used in NICUs [4], although it can lead to unnecessary
exposure to antibiotics, can increase the risk of neonatal
death, and can cause selective pressure for antibiotic* Correspondence: chiara.pandolfini@marionegri.it
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reproduction in any medium, provided the orresistance, making it fundamental to employ only the
best possible options and only when necessary [5-9].
Efficacy data on antifungals in the treatment of invasive
fungal infections in preterm infants is lacking and more
data on their use in the prevention of such infections are
needed as well [10,11], although partial guidelines do
exist [12-14].
Italy has been playing a lead role in the investigation
of neonatal infections, also as a result of the activities of
a collaborative network, the GSIN (Gruppo di Studio
delle Infezioni Neonatali), specifically dedicated to per-
forming studies in this area [15-17].
A European project called Treat Infections in Neonates
(TINN), coordinated by the French National Institute for
Health and Medical Research in France and the Universityral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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safety and efficacy of ciprofloxacin and fluconazole in pre-
term and term neonates, is currently running [18]. The
project involves partners in 7 countries and is supported by
the European Commission. Ciprofloxacin and fluconazole
are being studied because they are present in the European
Medicines Agency’s priority list of therapeutic areas that
need specific drug evaluation in preterm and term neonates
[19]. As part of the TINN project, a European survey on
the use of ciprofloxacin for treatment, and fluconazole for
treatment and prophylaxis, of invasive infections in neo-
nates was carried out [20,21]. The main objective was to
describe the current use of the two drugs in NICUs in
order to better orient the efforts of the entire TINN pro-
ject towards the creation of necessary knowledge on the
optimal use of these drugs.
Of all European NICUs that participated in the survey,
Italy was the most represented country, both in terms of
number of NICUs and homogeneity of their profile (all
level III units). In the present paper, we focus on the
Italian findings of the survey in order to describe the na-
tional practices concerning neonatal sepsis.
Methods
All Italian level III NICUs were contacted via email be-
tween December 2009 and May 2010 with both a letter of
invitation to participate in the survey and a commitment
to provide all participants with a report of the survey’s
results.
A questionnaire collecting information on the charac-
teristics of each unit, its use of ciprofloxacin and fluco-
nazole, and its involvement in clinical research was
created by the TINN partners, based in part on a US
survey [22]. The survey was tested by a group of part-
ners, and an online version for input was set up and sent
to each Italian NICU.
A number of questions assessing the factors that influ-
ence the NICU’s policies regarding ciprofloxacin and fluco-
nazole were included, and an additional email requesting
missing data was sent in June 2010 to NICUs who had al-
most completed all the questions necessary for their
records to be considered in the analysis.
Statistical analysis
A methodology similar to that employed in the US survey
by Burwell [22] was used in order to enhance comparison
of the respective results. Another, more recent study from
UK and Ireland also used a similar questionnaire, but it
was administered to individual physicians so data does not
refer to individual intensive care units [23]. The answers
to the questions included in the questionnaire were mea-
sured on a 5-point Likert scale (1: least important, 5: most
important). The mean and 95% confidence intervals were
calculated for the 5-point Likert scale responses. Sincemost of the means were between 3 and 4, the responses
were dichotomized and those ≥ 4 were categorized as im-
portant and those ≤ 3 as less important. Respondents were
grouped into those who used ciprofloxacin and those who
did not, and those who used fluconazole and those who
did not. Categorical variables were compared by χ2 ana-
lysis and P values are 2-tailed. The survey data collected
was managed using Microsoft Access and analyzed using
SAS (Vers. 9.13, SAS Institute, Inc. Cary, NC).
The “Mario Negri” Institutional review board ruled the
study exempt from ethical approval.
Results
Data were obtained from 38 Italian NICUs, 36% (38/
105) of the country’s level III centers. Over half (53%)
the NICUs have 1–10 cases of bacterial sepsis monthly,
while 42% have less than 1. The reported prevalence of
fungal infections is <1% in 50% of the NICUs and is ≤
5% in 90%.
In terms of geographical distribution, almost half (47%)
of the NICUs that participated are located in northern
Italy, while 19% are in central and 34% in southern Italy.
The proportion of participating NICUs compared to the
number of NICUs present in each of the three geograph-
ical areas is similar; no statistically significant difference
was found (p=0.36). The data would therefore seem to be
representative of the regional distribution of NICUs.
Most of the NICUs (71%) have a standard written proto-
col on antibiotic treatment in case of suspected bacterial
sepsis, 82% have one on routine antifungal prophylaxis,
and 70% have one on antifungal treatment. 47% of NICUs
have protocols covering all three conditions.
Ciprofloxacin treatment
Only 5 NICUs (13%) ever use ciprofloxacin. The indica-
tions for initiating treatment vary between NICUs
[Table 1]. All 5 administer the drug intravenously, but at
different dosages: three administer an average dose of
20 mg/kg/day (at 12 hour intervals), while the other two
administer 10 mg/kg/day (one at 8 hour intervals and
the other at 12). Concerning the average duration of
treatment, only one center replied, reporting 10 days.
Among the factors influencing the decision to use
ciprofloxacin or not, the two ranked most important
were uncertainty about the safety of the drug and the
fact that ciprofloxacin should be reserved for infections
with multi-drug resistant micro-organisms (average rat-
ing of each factor, from 1 to 5: 4,2).When NICUs using
ciprofloxacin were compared with those not using it, the
numbers were unbalanced, but they seemed to show no
significant difference in importance attributed to the
listed factors [See Additional file 1 for data].
No guidelines on the use of ciprofloxacin for sepsis
were found. The British national Formulary for Children
Table 1 Indications for initiation of treatment or prophylaxis with the two drugs
Ciprofloxacin treatment (5 NICUs) N. NICUs
First line therapy (even in association) of:
Culture-proven sepsis due to multi-drug resistant organisms that are sensitive to ciprofloxacin 5 (100%)
Sepsis resulting from a suspected multi-drug resistant strain infection 1
Sepsis resistant to first line empirical antibiotic therapy (other than ciprofloxacin) 1
Severe sepsis resistant to first line empirical antibiotic therapy (other than ciprofloxacin) 1
Fluconazole prophylaxis (30 NICUs)













Presence of a central venous catheter (CVC) 22 (73%)
Peripherally inserted CVC 18
Umbilical venous CVC 15
Only CVC used >7 days 7
Only CVC used >14 days 1
Surgically inserted CVC 5
Endotracheal intubation 10 (33%)
Only if intubated >7 days 8
Only if intubated >14 days 0
Total parenteral nutrition (TPN) 14 (47%)
Only if TPN used >7 days 11
Only if TPN used >14 days 1
Abdominal surgery 12 (40%)
Abdominal disease 7 (23%)
Necrotizing enterocolitis 4
Focal bowel perforation 3
Gastroschisis 1
Omphalocele 0
Antibiotics being used 5 (17%)
Only if >7 days 5
Only if >14 days 0
Colonization status 11 (37%)
Scheduled surveillance cultures+/− other cultures 7
Determined by clinical features 4
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Table 1 Indications for initiation of treatment or prophylaxis with the two drugs (Continued)
Fluconazole treatment (17 NICUs)
Sepsis with identification of Candida spp. in cultures of central samples (blood, cerebrospinal fluid, . . .) 15 (88%)
Sepsis with documented fungal colonization 12 (71%)
Sepsis resistant to first line empirical antibiotic therapy 7 (41%)
Severe sepsis 1 (6%)
Note: some answers were missing so sum is not always equal to number of NICUs replying.
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treating neonatal bacteremia and mentions that ciproflox-
acin is used in cases of septicemia caused by multiresistant
organisms, but does not address the drug directly.
Fluconazole prophylaxis
Overall, 30 NICUs (79%) declare using fluconazole for
prophylaxis. No significant correlation was found between
use of fluconazole prophylaxis and prevalence of fungal
infections in the NICUs (Fisher's exact test P-value 1.0000).
In the centers that use fluconazole for prophylaxis, birth
weight is an important variable guiding the decision to
employ prophylaxis for 90% of them. Of these centers,
48% use <1500 g as a cutoff, 48% use <1000 g, and the
remaining NICU uses <750 g as cutoff. There was wide
variation in the indications for initiating prophylaxis
between NICUs [Table 1].
Differences were found between the 30 NICUs in the
dosage schemes used as well. The majority (76%) admin-
ister an average dose of 3 mg/kg, while the rest adminis-
ter 6 mg/kg. Of those who use 3 mg/kg, a little more
than 50% administer it every 72 hours, 36% every
48 hours. Of the 7 centers who use 6 mg/kg, 4 adminis-
ter it every 72 hours and the rest every 48, 24, or “other”
hours (1 each). Most NICUs (89%) administer the drug
intravenously, while the rest administer it orally.
Concerning the duration and withdrawal of prophylaxis,
almost half (47%) reported having a fixed average duration
of prophylaxis, which ranged from 10 to 45 days (median
30). Few centers reported using corrected gestational age
or target weight reached as parameters (2 and 1 NICUs,
respectively), while 12 (40%) reported unavailability of an
IV route as a criterium. In cases of confirmed fungal infec-
tion in neonates receiving prophylactic fluconazole, 14
(47%) of the NICUs report using liposomal amphotericin
B, 2 report amphotericine, 4 fluconazole at increased,
therapeutic dosages, 2 flucytosine, and 1 caspofungin (in
cases of resistance).
NICUs who did not use fluconazole prophylaxis were
significantly more likely to be concerned about the exist-
ing uncertainty regarding the drug’s safety in newborns
(p<0.01). The need for a statement by pediatric societies
in support of the routine use of fluconazole for prophy-
laxis and the need for additional efficacy studies were
also considered important factors (average importance,from 1 to 5: 3.5 and 3.3, respectively) [See Additional file
1 for data].Fluconazole treatment
Almost half (17) of NICUs administer fluconazole for
treatment. Of the centers with a protocol (26/38), over
half (56%) don’t use fluconazole. Overall, 12 NICUs use
fluconazole for both prophylaxis and treatment. Most of
the NICUs (15/17) use fluconazole in cases of neonatal
sepsis with identification of Candida spp in cultures of
central samples, although there was some variation in
indications for starting treatment also for fluconazole
[Table 1].
Fluconazole treatment schemes between NICUs were
also found to vary. Dosages ranged from 3 to 12 mg/kg/
daily, considering the different average single doses and
the intervals applied between administrations. Most of
the NICUs (15/17) administer fluconazole intravenously.
The average duration of treatment ranges from 10 to 30
days. The current first line antifungal, other than fluco-
nazole, used in NICUs is liposomal amphotericin B in 8
centers and amphotericin B in 2.
Current guidelines [13] on treatment of neonatal can-
didiasis recommend amphotericin B or, as a reasonable
alternative, fluconazole at a dosage of 12 mg/kg daily for
3 weeks. Of the 17 NICUS that use fluconazole, 5 ad-
minister it at the recommended dosage, and for more or
less the recommended length of therapy (3 administer it
for 3 weeks, 1 for 28 days, and 1 for 15–21 days). All the
rest administer lower dosages, either because of a lower
unit dose or because the same dose is given less fre-
quently. When transformed into daily doses: 9 NICUs
give 6 mg/kg/day, 1 gives 4 mg/kg/day, 1 gives 3 mg/kg/
day, and 1 does not specify frequency.
The factors potentially influencing the NICUs’ choice
to use fluconazole for treatment were not considered
very important by the NICUs. In fact, the highest aver-
age importance attributed was 3.3 and concerned two
factors: the need for a statement by pediatric societies
supporting the selection of the drug and the need for
additional efficacy studies. No significant differences
were found in the importance given to the different fac-
tors by NICUs who use the drug and those who don’t
[See Additional file 1 for data].
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Although all Italian level III NICUs were invited to join
the survey, it is likely that those that participated are
more active in research and/or are more interested in
self-audit and improvement of a unanimously acknowl-
edged clinical care. Nevertheless, a third of all the Italian
NICUs participated and represent the north, center, and
south of Italy. Besides the geographic distribution, the
estimated rate of admission of newborns <32 weeks’ ges-
tational age in participating NICUs (0.85%) is close to
that reported in Italy (0.9%) [25] and also supports the
representativeness of collected data at the national level.
The wide variation in dosages used does not seem to de-
pend on area of the country and, in any case, highlights
the need for national, or better international, shared
guidelines incorporating current knowledge on the treat-
ment of neonatal sepsis.
Ciprofloxacin treatment
Almost three quarters of Italian NICUs have a standard
written protocol regarding antibiotic treatment for sus-
pected sepsis, and very few use ciprofloxacin. The Italian
data was in line with European data [20] in terms of limited
use of ciprofloxacin and concern about bacterial resistance
and drug safety. Concern about antibiotic resistance, how-
ever, was not enough to dissuade centres from using the
drug. The ciprofloxacin dosages used varied, but the NICUs
using this drug were few so no conclusions can be made.
Fluconazole use
Fluconazole prophylaxis has been found to reduce the
incidence of invasive fungal infection in VLBW infants,
and recent data on long term outcomes and antifungal
resistance seem positive so far [26,27]. This study’s data
show that, in Italy, a majority of NICUs (79%) use fluco-
nazole prophylaxis, a rate much higher than that found
in all the European NICUs participating in the survey
[20] and in the UK/Ireland and US studies [22,23]. Rates
of prophylaxis in different studies may be based on inci-
dence, but rates in infants at the lower gestational ages
are high in all studies. No correlation was found between
reported prevalence of fungal infections in the NICUs
and their choice to use fluconazole prophylaxis. The
reported incidence in the survey fits within the range
reported by other studies [28], although methodologies
in data collection differ and direct comparison with inci-
dence data is not possible. Incidence rates of fungal in-
fection differ between studies, from 2,6 to 9% [29,30]. A
large part of the variation in rates is due to the number
of extremely low birth weight infants admitted at each
NICU [31,32], but may also reflect differences in clinical
practices [33].
There was variation between the centers concerning
the indications for initiating fluconazole prophylaxis, butbirth weight, presence of a central venous catheter, and
gestational age were considered the most important and
these data are similar to those found by Burwell et al
[22]. The guidelines addressing prophylaxis [12,13] only
take into account birth weight and rate of disease in hos-
pital units as the factors on which to base prophylaxis
initiation, while other factors should also be considered
[34]. Guidelines use birth weight as an indicator, for ex-
ample, but gestational age has a more linear relationship
with invasive candida infection [35]. Furthermore, the
guidelines should be updated to reflect the finding that
fluconazole prophylaxis can reduce incidence even in
NICUs with a low rate of invasive candida infection
[34]. It has been shown that implementing a guideline
that includes specific criteria for identifying high-risk
VLBW infants reduced invasive fungal sepsis rates with-
out evidence of fluconazole resistance emerging [36].
The possibility of resistance emerging, as well as insuffi-
cient safety data, make the creation of standard, more
accurate guidelines identifying newborns at the highest
risk of acquiring fungal infection, and therefore candi-
dates for prophylaxis, a high priority.
The main guidelines on candidiasis [13] suggest con-
sidering fluconazole prophylaxis in neonates with birth
weights <1000 g, and at a dosage of 3 mg/kg iv every
72 hours for the first 2 weeks of life, every 48 hours dur-
ing the third and fourth weeks, and daily in the fifth and
sixth weeks of life. The other cited guidelines [14] offer
limited information on prophylaxis, but the initial dose
is similar. Dosage data from the NICUs refers to a single
dose only, so a comparison with the dosage change over
time, as specified in the main guidelines, is not possible,
however, 38% of the NICUs report using the same dosage
and route as the guidelines, i.e. 3 mg/kg every 72 hours
intravenously. Only one center followed the guidelines
completely, considering also duration of prophylaxis. The
US survey did not assess dose, and data from the UK/Ire-
land study, which is not directly comparable because it
involved individual physicians, had almost half the
responses reporting the use of 3 mg/kg and almost one
fourth 6 mg/kg, compared to three fourths using the lower
dose in the Italian data. Studies have been performed to
test less intensive dose regimens, including twice weekly
dosing [17,37], and their results were encouraging, but
additional trials are needed to identify the most appropri-
ate dosing regimen [10].
Significant concern about safety in using fluconazole
for prophylaxis resulted from the data. This differs from
the US data [22], which revealed concern especially
about resistance, and the UK/Ireland data [23], which
emphasized the importance or the perceived level of in-
vasive candidiasis in the unit. Even when compared with
the data from all the European NICUs surveyed [20],
showing that those that don’t use prophylaxis were more
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of a statement by pediatric societies promoting routine
use in a subset of newborns, concerns seem to differ. To
reduce the possibility of resistance in cases of fungal infec-
tion in infants following fluconazole prophylaxis, treat-
ment with a different antifungal than fluconazole should
be initiated [34]. Only 19/30 of the NICUs reported using
a drug other than fluconazole in cases of confirmed fungal
infection in patients under fluconazole prophylaxis. The
guidelines should address this issue specifically.
Half of the NICUs use fluconazole for treatment of fun-
gal sepsis, and only about one third follow the guideline
recommendations on dosage, while the rest use lower
dosages. Concerning the indications for starting treatment
with fluconazole, the majority of NICUs that use the drug
follow the guidelines in that they initiate treatment when
sterile body fluids test positive for Candida spp. There did
not seem to be general concern over safety, but some
interest was expressed for both the need for an official
statement supporting the choice of fluconazole and for
more efficacy studies. These, however, did not seem to be
valid indicators in the choice to not use the drug. The
emerging picture concerning fluconazole treatment is that
there is a need for more guidance for clinicians, through
greater acknowledgement of the existing guidelines and
acquisition of additional data on the drug.
One of the major limits of this study was the sample
size. The Italian data originated from 38 NICUs and this
limited data comparison.
Researchers in Italy have attempted to prioritize shared
information on the care of extremely low birth weight ba-
bies [38,39], but the situation needs further developments.
The collection of data on rates of infection by a centra-
lized, international public body would permit transparency
and homogeneous, accurate data on incidence, and this
would, in turn, motivate centers to implement the most
effective, evidence based practices.
The TINN project has already begun to improve the
availability of information on fluconazole and ciprofloxacin,
as also documented in published articles [20,40,41], and
will provide additional clinical evidence in the early future.
Conclusions
This national survey confirms the existence of very differ-
ent approaches between NICUs towards the prevention
and management of neonatal sepsis. The heterogeneity of
the dosage schemes clearly demonstrates the lack of solid,
acknowledged guidance, and probable lack of awareness of
existing guidance.
The lack of hard evidence leads to different approaches
and to the request for indications by third parties (i.e. sci-
entific societies).
Common approaches are needed to standardize and
update a national drug strategy for the prevention andtreatment of sepsis in very low birth weight newborns.
This can be achieved through collaborative initiatives
aimed at setting up guidelines based on available data.
The survey described in this article was a first step in ac-
quiring data to stress the need for guidelines, to orient
their contents towards the areas in greatest need of in-
formation, and to support neonatal societies in their cre-
ation. Formal international consensus statements, such
as those that will be produced by the TINN network,
will contribute to a more homogeneous and rational ap-
proach to neonatal sepsis prophylaxis and treatment in
NICUs worldwide.
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